相关临床试验
91
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
62
68.1%
终止
26
28.6%
撤回
3
3.3%
暂无批准数据
- EMD Serono, the US and Canada healthcare business of Merck KGaA, has acquired two AI-designed fertility programs from Boston-based PostEra for a mid-double-digit millions sum. - The programs comprise oral small molecule agonists of follicle-stimulating hormone receptor for IVF ovarian stimulation and luteinizing hormone/choriogonadotropin receptor for male infertility and ovulation trigger. - PostEra used its Proton AI platform to overcome historical hurdles in drugging these biologic-validated targets, including selectivity and metabolic stability, with both candidates still in preclinical development. - A combination of the two agonists could shift IVF protocols from injections to an all-oral regimen, while PostEra retains its polyendocrine metabolic ovarian syndrome program and plans trials next year.
- Lucid Group has appointed Eric Muller, former Group President and COO of Publicis Health, as its new Chief Executive Officer, effective August 19, 2026. - Muller succeeds Rick Sannem, the original DiD Agency founder, who will transition to the role of Strategic Advisor to the Board. - The leadership change reflects Lucid's strategy to expand its global footprint and strengthen its data, AI, and technology capabilities across healthcare commercialization. - Muller cited Lucid's strong scientific backbone and medcomms/medical affairs expertise as key differentiators in serving pharma and life sciences clients.
- Inductive Bio placed first in OpenADMET's PXR Blind Challenge, outperforming more than 350 researchers from large pharma, biotech, and academic organizations. - The company's Beacon AI model has now won three consecutive independent blind challenges, a record unmatched by any other AI drug discovery company. - The PXR challenge focused on predicting pregnane X receptor activation, a common liability that often goes undetected until mid- to late-stage lead optimization. - Inductive Bio is also leading an up to $21M ARPA-H CATALYST award with Amgen to build AI models for drug-induced liver injury and cardiotoxicity prediction.
- Synthetic real-world data generated by AI can replicate survival outcomes and clinical patterns from real patient cohorts while protecting patient privacy, according to research presented at ESMO Congress 2025. - A classification and regression tree (CART) model demonstrated the highest fidelity to the source cohort of 19,164 metastatic breast cancer patients, with re-identification risk below 2%. - Synthetic datasets can facilitate data sharing, optimize clinical trial design through external control arms, and enable patient matching for outcome prediction. - Experts caution that synthetic data may amplify biases from source data and cannot replace real-world data or clinical trials, with clinical validation remaining indispensable.
- The Trump Administration announced landmark agreements with Eli Lilly, Novo Nordisk, and Gilead Sciences that reduce prescription drug costs by up to 79% through Most Favored Nation pricing deals. - Ozempic and Wegovy prices will drop from over $1,000 monthly to $350, while future oral GLP-1 drugs will launch at $150 per month, with Medicare covering anti-obesity medications for the first time. - The deals mandate historic US manufacturing investments totaling over $69 billion, including Eli Lilly's $27 billion expansion and Novo Nordisk's $10 billion commitment to domestic production. - Gilead Sciences agreed to provide hepatitis C treatment Epclusa through a direct-to-patient program and will invest $32 billion in US-based manufacturing and R&D over five years.
- Merck's cladribine capsules have received FDA Fast Track designation for treating generalized Myasthenia Gravis, potentially becoming the first oral treatment for this rare autoimmune neuromuscular disorder. - The drug previously received Orphan Drug Designation and is currently being evaluated in the global Phase 3 MyClad trial involving 264 patients with gMG. - Cladribine targets B and T cells that produce harmful autoantibodies causing inflammation at the neuromuscular junction, offering a convenient oral regimen for patients. - Merck has established a patient council and collaborates with over 20 advocacy groups worldwide to ensure the clinical program meets patient needs.
- Pimicotinib demonstrated an increasing objective response rate from 54% at Week 25 to 76.2% at 14.3 months median follow-up in the global Phase 3 MANEUVER trial for tenosynovial giant cell tumor patients. - The CSF-1R inhibitor showed continued improvements in patient-reported outcomes including range of motion, pain reduction, and physical function beyond one year of treatment. - China's NMPA has accepted the marketing authorization application for pimicotinib as a Class 1 innovative drug, with additional regulatory submissions planned for the U.S. and other markets. - Safety profile remained consistent with no new signals, including no evidence of cholestatic hepatotoxicity or drug-induced liver injury at extended follow-up.
- President Trump announced a deal with EMD Serono to reduce fertility medication costs, with Gonal-f available at an 84% discount for IVF patients. - The agreement aims to lower per-cycle IVF drug costs by an estimated 73% for American consumers, addressing affordability barriers for fertility treatments. - Administration officials say the deal will help millions of U.S. women who struggle with conception access necessary medications more affordably. - The initiative includes working with employers to expand supplemental insurance coverage for fertility treatments, as only 30% of families currently have employer coverage.
- New four-year data from CLARIFY-MS and MAGNIFY-MS studies demonstrate that 89.2% of relapsing multiple sclerosis patients treated with MAVENCLAD remained free from progression independent of relapse activity. - The oral therapy reduced key neuroinflammation biomarkers in cerebrospinal fluid and serum, with brain atrophy rates comparable to healthy populations from years 2 to 4. - Over 130,000 patients have been treated with MAVENCLAD since its 2019 launch, representing the only high-efficacy short-course oral treatment for relapsing MS that doesn't require continuous immunosuppression.
- A phase II clinical trial demonstrated that combining avelumab and cetuximab nearly quadrupled median progression-free survival compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma. - The combination therapy achieved a median progression-free survival of 11.1 months versus 3.0 months for avelumab monotherapy, with a hazard ratio of 0.48 and statistical significance. - The study enrolled 57 evaluable patients with advanced cSCC, showing that dual immunotherapy targeting both PD-L1 and EGFR pathways creates synergistic anti-tumor effects. - Results provide valuable insights for future trials combining standard-of-care immunotherapies with cetuximab to improve outcomes in this aggressive skin cancer.
